Product Details
ORENCIA 250MG/15ML VIAL EA
Manufacturer: Bristol Myers
MFG#: 00003-2187-13
NDC: 00003-2187-13
PID: 659476
1/UN
$ *.**
In Stock1/EA
$ *.**
In Stock1/VL
$ *.**
In StockAdditional Information
| Product Name | Orencia 250 mg/ 15ml Vial Each |
| Active Ingredient | Abatacept |
| Mechanism of Action | Selective T-cell costimulation modulator |
| Dosage Form | Lyophilized Powder for Injection |
| Strength | 250 mg per 15 ml |
| Route of Administration | Intravenous (IV) Infusion |
| Reconstitution Required | Yes, with Sterile Water for Injection |
| Dilution Required | Yes, with 0.9% Sodium Chloride Injection |
| Infusion Time | Administered over 30 minutes |
| Dosing Schedule | Baseline, Weeks 2 & 4, then every 4 weeks |
| For Use In | Adults and children (2 years and older) |
| Incompatibility | Should not be used with TNF inhibitors or JAK inhibitors |
| Container Type | Single-Dose Vial |
| Storage Requirements | Refrigerated (2°C to 8°C / 36°F to 46°F) |
| Application | Rheumatoid Arthritis, Psoriatic Arthritis, pJIA |
Description
Orencia (abatacept) is a selective T-cell costimulation modulator indicated for the treatment of moderate to severe rheumatoid arthritis (RA) in adults who have had an inadequate response to other disease-modifying antirheumatic drugs (DMARDs). Orencia can be administered alone or in combination with non-biologic DMARDs but should not be used with Janus kinase (JAK) inhibitors or biologic DMARDs, such as tumor necrosis factor (TNF) antagonists.
Orencia is also approved for the treatment of moderate to severe polyarticular juvenile idiopathic arthritis (pJIA) in patients aged two years and older. It may be used as monotherapy or in combination with methotrexate (MTX). By targeting immune system dysregulation, Orencia helps manage joint inflammation, prevent disease progression, and improve overall physical function in pediatric patients.
For patients with active psoriatic arthritis (PsA), Orencia reduces signs and symptoms of the disease and prevents structural joint damage. It is approved for use in adults either as monotherapy or in combination with non-biologic DMARDs. In pediatric patients, it may be used alone or with MTX to control inflammation and minimize disease progression.
Frequently Asked Questions (FAQs)
The cost of ORENCIA 250MG/15ML VIAL EA is $$0.00
ORENCIA 250MG/15ML VIAL EA is manufactured by Bristol Myers.
You can purchase ORENCIA 250MG/15ML VIAL EA on our website at https://cobalt.pipelinemedical.com/product/detail/orencia-250mg-15ml-vial-ea-659476